We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+4.51%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$791M
AUM Growth
-$79M
Cap. Flow
-$79.2M
Cap. Flow %
-10.01%
Top 10 Hldgs %
32.88%
Holding
105
New
11
Increased
29
Reduced
37
Closed
15

Top Buys

Rank Stock Value
1
DHR icon
Danaher
DHR
+$15.4M
2
LLY icon
Eli Lilly
LLY
+$12.5M
3
EHC icon
Encompass Health
EHC
+$11.3M
4
CAH icon
Cardinal Health
CAH
+$8.16M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$6.81M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$19.8M
2
UNH icon
UnitedHealth
UNH
+$18M
3
PRCT icon
Procept Biorobotics
PRCT
+$14.6M
4
MOH icon
Molina Healthcare
MOH
+$14.4M
5
MCK icon
McKesson
MCK
+$13.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UHS icon
51
Universal Health Services
UHS
$10.5B
$4.71M 0.6%
+26,000
New +$4.69M
SYK icon
52
Stryker
SYK
$133B
$4.55M 0.58%
+11,500
New +$4.3M
TMO icon
53
Thermo Fisher Scientific
TMO
$222B
$4.52M 0.57%
11,140
-1,500
-12% -$627K
ACLX
54
DELISTED
Arcellx
ACLX
$4.43M 0.56%
67,250
+23,750
+55% +$1.48M
EW icon
55
Edwards Lifesciences
EW
$53B
$4.3M 0.54%
+55,000
New +$4.1M
TGTX icon
56
TG Therapeutics
TGTX
$7.52B
$4.14M 0.52%
115,000
-62,500
-35% -$2.33M
NUVL
57
DELISTED
Nuvalent
NUVL
$4.01M 0.51%
52,500
– –
INSP icon
58
Inspire Medical Systems
INSP
$1.73B
$3.96M 0.5%
30,500
+14,500
+91% +$2.1M
BNTX icon
59
BioNTech
BNTX
$23.3B
$3.82M 0.48%
35,870
+120
+0.3% +$12.1K
CYTK icon
60
Cytokinetics
CYTK
$10.5B
$3.44M 0.44%
104,250
– –
RARE icon
61
Ultragenyx Pharmaceutical
RARE
$2.64B
$3.39M 0.43%
93,100
+11,100
+14% +$400K
MIRM icon
62
Mirum Pharmaceuticals
MIRM
$6.02B
$3.35M 0.42%
65,755
-8,000
-11% -$356K
GPCR icon
63
Structure Therapeutics
GPCR
$3.82B
$2.8M 0.35%
135,100
+65,100
+93% +$1.43M
RDNT icon
64
RadNet
RDNT
$6.08B
$2.62M 0.33%
+46,000
New +$2.53M
VCEL icon
65
Vericel Corp
VCEL
$2.25B
$2.47M 0.31%
+58,000
New +$2.41M
RGEN icon
66
Repligen
RGEN
$9.21B
$2.43M 0.31%
19,500
+15,000
+333% +$1.91M
LIVN icon
67
LivaNova
LIVN
$4.21B
$2.39M 0.3%
+53,000
New +$2.19M
DNTH icon
68
Dianthus Therapeutics
DNTH
$6.25B
$2.36M 0.3%
126,627
– –
VKTX icon
69
Viking Therapeutics
VKTX
$4.02B
$2.25M 0.28%
85,000
-15,000
-15% -$395K
MLTX icon
70
MoonLake Immunotherapeutics
MLTX
$1.47B
$2.12M 0.27%
45,000
– –
NRIX icon
71
Nurix Therapeutics
NRIX
$2.69B
$2.11M 0.27%
185,000
-64,336
-26% -$695K
PRVA icon
72
Privia Health
PRVA
$2.86B
$2.1M 0.27%
91,189
-7,000
-7% -$162K
IQV icon
73
IQVIA
IQV
$39.8B
$2.05M 0.26%
13,000
-9,000
-41% -$1.35M
KRYS icon
74
Krystal Biotech
KRYS
$9.81B
$1.75M 0.22%
12,750
-5,000
-28% -$734K
SMMT icon
75
Summit Therapeutics
SMMT
$11.9B
$1.66M 0.21%
+78,000
New +$1.78M
1 2
3
4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2025 Portfolio in Review

As of Q2 2025, Rhenman & Partners Asset Management held 105 positions worth $791M, down 9.1% from $870M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $79.2M in Q2 2025, closing 15 positions and reducing 37 holdings. Its most notable exit was Bristol-Myers Squibb, an estimated $19.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Rhenman & Partners Asset Management opened a new position in Cardinal Health worth $9.24M.

  • Rhenman & Partners Asset Management's largest Q2 2025 buy was Cardinal Health: 55,000 shares worth $9.24M.
  • Rhenman & Partners Asset Management added most to Danaher in Q2 2025, an estimated $15.4M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2025 reduction was UnitedHealth, cutting an estimated $18M.
  • Rhenman & Partners Asset Management fully exited Bristol-Myers Squibb in Q2 2025, selling an estimated $19.8M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 33% of its $791M portfolio in Q2 2025.
  • Rhenman & Partners Asset Management opened 11 new positions and closed 15 in Q2 2025.
  • Rhenman & Partners Asset Management's portfolio value fell 9.1% quarter-over-quarter to $791M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2025, filed 13 Aug 2025.